ICIs are safe and effective for HIV-positive NSCLC patients, with no significant differences in survival outcomes compared to ...

CMS introduced the GENEROUS Model to reduce Medicaid drug costs, enhance access, and improve health outcomes for ...

Explore how the WISeR Model addresses prior authorization reform, Medicare costs, and AI's role in tackling the health care ...

Lumateperone is approved as an adjunctive treatment for MDD, expanding its indications beyond schizophrenia and bipolar ...

A new option is now approved to treat adults living with high-risk smoldering multiple myeloma. 1 The FDA has greenlit ...

Eli Lilly and Novo Nordisk will lower prices for GLP-1 receptor agonists, aligning with the Most Favored Nation executive ...

Panelists discuss how sequencing decisions favor early use of the most potent therapies to extend survival in EGFR-positive ...

In late September, oncology experts gathered in Nashville, Tennessee, for the 2025 Patient-Centered Oncology Care ® conference. Over 2 days, 15 panel discussions explored topics aligned with this year ...

Remibrutinib shows promise in treating generalized myasthenia gravis, with ongoing trials assessing its efficacy and safety for patients.

1. Willi R, Bril V, Howard J, et al. RELIEVE: a phase 3 study evaluating the efficacy and safety of remibrutinb in generalized myasthenia gravis. Presented at: American Association of Neuromuscular & ...

Medicare Advantage plans that place greater restrictions on home health agency care delivery may have more adverse patient outcomes than plans that provide episodic payments.

For Medicaid care management, focusing on rising-risk patients is more effective than targeting high-cost claimants, whose spending tends to decrease over time due to regression to the mean.